Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2026

Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: A post hoc analysis of Phase III and long-term extension trials

BMJ Open 2025;15:e082366 Doi: 10.1136/bmjopen-2023-082366

Strand et al. showed that TOF was efficacious across both sexes, with higher responses in males observed particularly for more stringent composite endpoints and PROs. Authors conducted a post hoc analysis of placebo-controlled RCTs to evaluate TOF efficacy, safety, and persistence by sex, and explored whether age-related factors contribute to differences in treatment response between males and females.

Keywords:

June 2025

Deucravacitinib in patients with plaque psoriasis who screened positive for psoriatic arthritis: improvements in joint pain and the impact of musculoskeletal symptoms

Dermatol Ther (Heidelb) 2025 DOI: 10.1007/s13555-025-01428-9

Varga S,

Choi JC,

Zhong Y,

Bili A,

Merola et al. undertook a post hoc analysis of prospective cohorts that compared the effects of deucravacitinib vs placebo and vs apremilast on joint pain, and the impact of musculoskeletal symptoms, at Weeks 16 and 24 in the pooled POETYK PSO-1 and PSO-2 populations who self-reported joint symptoms on the PASE questionnaire. Patients who screened positively for PsA reported greater improvements in joint pain and peripheral joint disease with deucravacitinib vs placebo at Week 16 and vs apremilast at Week 24. Findings from this pooled analysis suggest that deucravacitinib may be used to treat both dermatologic and joint symptoms effectively in patients with psoriasis and probable arthritis.